IPSEN (IPSEY)
(Delayed Data from OTC)
$31.19 USD
+1.03 (3.42%)
Updated Apr 26, 2024 11:04 AM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IPSEY 31.19 +1.03(3.42%)
Will IPSEY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IPSEY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPSEY
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
Is IPSEN (IPSEY) Outperforming Other Medical Stocks This Year?
IPSEY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen
Other News for IPSEY
Ipsen price target raised by EUR 2 at Deutsche Bank
Ipsen S.A. reports Q1 results; reaffirms full-year guidance
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Ipsen, Skyhawk Therapeutics announce worldwide RNA targeting collaboration
Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases